Teva Pharmaceutical Says FDA Approves AirDuo Digihaler Inhalation Powder
By Michael Dabaie
Teva Pharmaceutical Industries Ltd. (TEVA) said the U.S. Food
and Drug Administration approved AirDuo Digihaler Inhalation
That is a combination therapy digital inhaler with built-in
sensors that connects to a companion mobile application for
information on inhaler use to people with asthma.
AirDuo Digihaler is indicated for the treatment of asthma in
patients aged 12 and older.
The approval of AirDuo Digihaler is based on the review of the
supplemental new drug application Teva submitted to the FDA.
Write to Michael Dabaie at email@example.com
(END) Dow Jones Newswires
July 15, 2019 09:18 ET (13:18 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.